Coxib Imaging Conjugates for Precise COX-2 Pathology Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying the site of pathology, particularly for tumors and inflammation, are often invasive, costly, and inaccurate, leading to challenges in diagnosis and treatment.
Innovation Solution
Development of coxib-derived conjugate compounds, such as those containing valdecoxib and celecoxib, linked with imaging moieties like technetium-99m, rhenium, or manganese, to non-invasively locate sites of pathology and inflammation by targeting cyclooxygenase enzyme expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional screening methods (MRI, blood tests) are used to detect tumors and pathology, then diagnosis can be performed, but the methods are invasive, costly, and often inaccurate or non-specific
Solution Approach 1:
The patent uses coxib-derived conjugate compounds as intermediary agents that bind to cyclooxygenase enzymes at tumor sites and carry imaging moieties (such as technetium-99m, rhenium, or manganese) to the target location. This intermediary approach allows non-invasive detection through imaging techniques, avoiding the need for invasive biopsies or complex surgical procedures while maintaining diagnostic accuracy.
Solution Approach 2:
The patent replaces mechanical/invasive diagnostic procedures (such as biopsies, surgical explorations, or complex imaging sequences) with a biochemical-imaging approach. The coxib compounds target cyclooxygenase enzymes through biochemical binding, and the attached imaging moieties provide signal detection through radiation or magnetic resonance techniques, substituting mechanical intervention with non-invasive detection methods.
2Measurement precision
If conventional imaging methods are used to locate pathology, then localization can be attempted, but accuracy is insufficient and multiple tests are required
Solution Approach 1:
The patent segments the diagnostic process into a targeted molecular imaging approach rather than requiring multiple sequential tests. The coxib-derived conjugates specifically target cyclooxygenase enzymes that are overexpressed at tumor sites, allowing direct localization of pathology through a single imaging procedure. This segmentation of the diagnostic function into a focused molecular-targeted approach improves both accuracy and efficiency.
Solution Approach 2:
The patent changes the detection parameter from conventional anatomical imaging to molecular-level detection through imaging moieties that detect biochemical activity. By using radiotracers or magnetic resonance agents attached to coxib compounds, the diagnostic parameter shifts to detecting cyclooxygenase enzyme activity and prostaglandin synthesis, providing superior localization accuracy and reducing the need for multiple diagnostic tests.
3Ease of operation
If pain localization methods are used to identify pathology site, then patient comfort can be assessed, but the pain location does not always correspond to the actual pathology site
Solution Approach 1:
The patent uses coxib-derived conjugate compounds as intermediary agents that directly target cyclooxygenase enzymes at the actual site of pathology, regardless of where pain is perceived. This intermediary approach provides objective biochemical localization that is independent of the patient's subjective pain perception, resolving the discrepancy between pain location and pathology location.
Solution Approach 2:
The patent substitutes subjective pain assessment with objective biochemical imaging. Instead of relying on patient-reported pain location, the system uses molecular imaging to detect cyclooxygenase enzyme activity and prostaglandin synthesis at the actual site of pathology, providing precise localization that is not influenced by referred pain or patient perception limitations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid and accurate localization of tumors and inflammation sites, improving diagnostic accuracy and treatment efficacy by pinpointing areas of prostaglandin synthesis and COX enzyme overexpression.
Implementation Method 1
targeting cyclooxygenase enzyme expression
Implementation Method 2
containing valdecoxib and celecoxib, linked with imaging moieties like technetium-99m, rhenium, or manganese
Data Source
AI summary
Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The compounds contain a radioactive agent which permits imaging. The compounds concentrate at sites of increased cyclooxygenase expression, such as areas of increased COX-2 expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections, assessing efficacy of diagnosis and treatment of rheumatoid arthritis, and assessing the need for treatment with opioid drugs.